136 related articles for article (PubMed ID: 10894870)
1. Phase II evaluation of thalidomide in patients with metastatic breast cancer.
Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF
J Clin Oncol; 2000 Jul; 18(14):2710-7. PubMed ID: 10894870
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of thalidomide in patients with metastatic malignant melanoma.
Reiriz AB; Richter MF; Fernandes S; Cancela AI; Costa TD; Di Leone LP; Schwartsmann G
Melanoma Res; 2004 Dec; 14(6):527-31. PubMed ID: 15577325
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E
Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.
Varker KA; Campbell J; Shah MH
Cancer Chemother Pharmacol; 2008 Apr; 61(4):661-8. PubMed ID: 17589846
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
6. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SR; Ahern R; Smith IE; Gore ME
Br J Cancer; 2000 Feb; 82(4):812-7. PubMed ID: 10732751
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
8. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
9. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer.
Morabito A; Carillio G; Longo R; Gasparini G
Cancer J; 2005; 11(3):248-51. PubMed ID: 16053669
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.
Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Costa TD; Di Leone LP; Schwartsmann G
Invest New Drugs; 2003 Aug; 21(3):359-66. PubMed ID: 14578685
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Benbrook D; Darcy KM; Stearns-Kurosawa DJ; Eaton L; Yamada SD;
Gynecol Oncol; 2007 May; 105(2):508-16. PubMed ID: 17306350
[TBL] [Abstract][Full Text] [Related]
14. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.
Hernberg M; Virkkunen P; Bono P; Ahtinen H; Mäenpää H; joensuu H
J Clin Oncol; 2003 Oct; 21(20):3770-6. PubMed ID: 14551295
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
Rudek MA; Figg WD; Dyer V; Dahut W; Turner ML; Steinberg SM; Liewehr DJ; Kohler DR; Pluda JM; Reed E
J Clin Oncol; 2001 Jan; 19(2):584-92. PubMed ID: 11208854
[TBL] [Abstract][Full Text] [Related]
16. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.
Drake MJ; Robson W; Mehta P; Schofield I; Neal DE; Leung HY
Br J Cancer; 2003 Mar; 88(6):822-7. PubMed ID: 12644816
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
[TBL] [Abstract][Full Text] [Related]
18. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
